Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Status:
Recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a
different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial
have either spread to other parts of the body (metastatic) or cannot be removed completely
with surgery (unresectable).
All participants will get both tucatinib and trastuzumab. People with hormone-receptor
positive breast cancer will also get a drug called fulvestrant.
The trial will also look at what side effects happen. A side effect is anything a drug does
besides treating cancer.